Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML
(MedPage Today) -- Liposomal daunorubicin and cytarabine (Vyxeos) didn't hold up to standard daunorubicin/cytarabine induction therapy in children and young adults with newly diagnosed acute myeloid leukemia (AML), a phase III trial from the Children...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

